CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 167 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,882 | -20.7% | 468,055 | -2.2% | 0.00% | 0.0% |
| Q2 2023 | $16,239 | -36.8% | 478,574 | -32.9% | 0.00% | -50.0% |
| Q1 2023 | $25,675 | -30.8% | 713,562 | -14.3% | 0.00% | -33.3% |
| Q4 2022 | $37,127 | -99.8% | 833,009 | +11.7% | 0.01% | +100.0% |
| Q3 2022 | $20,972,000 | +45.8% | 746,008 | +39.9% | 0.00% | +50.0% |
| Q2 2022 | $14,381,000 | -60.0% | 533,402 | -49.4% | 0.00% | -50.0% |
| Q1 2022 | $35,910,000 | +1.5% | 1,054,325 | +15.2% | 0.00% | +33.3% |
| Q4 2021 | $35,379,000 | -25.4% | 915,608 | +4.2% | 0.00% | -25.0% |
| Q3 2021 | $47,425,000 | +264.5% | 878,409 | +125.8% | 0.00% | +300.0% |
| Q2 2021 | $13,010,000 | +90.1% | 389,048 | +17.1% | 0.00% | 0.0% |
| Q1 2021 | $6,844,000 | +33.3% | 332,230 | +13.4% | 0.00% | 0.0% |
| Q4 2020 | $5,135,000 | – | 293,068 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,605,390 | $71,552,232 | 10.98% |
| Octagon Capital Advisors LP | 761,398 | $33,935,509 | 5.28% |
| TSP Capital Management Group, LLC | 269,895 | $12,029,225 | 4.50% |
| Redmile Group, LLC | 1,977,451 | $88,134,991 | 3.60% |
| COMMODORE CAPITAL LP | 495,823 | $22,099 | 3.33% |
| Tri Locum Partners LP | 176,109 | $7,849,000 | 3.18% |
| ACUTA CAPITAL PARTNERS, LLC | 115,000 | $5,125,550 | 3.15% |
| Ikarian Capital, LLC | 267,476 | $11,921,406 | 2.88% |
| RTW INVESTMENTS, LP | 3,084,215 | $137,463,463 | 2.81% |
| Eversept Partners, LP | 558,774 | $24,904,557 | 2.18% |